Global Biotechnology industry revenue to reach $228.6 billion this year, Report – (MNKD, ARNA, LXRX, PPHM)

The biotechnology industry continues to be one of the few bright spots in the uncertain economic landscape. The latest report from industry research firm IBISWorld says that Global Biotechnology industry revenue is expected to reach $228.6 billion in 2012, having risen at an average rate of 10.4% per annum over the last five years.

The Biotech Index (IBB) gained 42.6% this year, while the S&P 500 gain was just 14.5%. As the country’s baby boomers continue to age, the demand for pharmaceuticals continues to move up and revenues of the biotechnology industry will advance, albeit at a weak compounded pace of 9% annually between 2012 and 2015.

MannKind Corporation (NASDAQ:MNKD) tumbled on Thursday after its decision to offer and sell shares of its common equity and warrants to acquire shares of its common stock in an underwritten public offering. Shares of this company traded down -24.23% during trading yesterday, hitting $2.01. The stock has a 52 week low of $1.57 and a 52 week high of $3.48. The company has a market cap of $392.79 million. The beta value is 1.01. MNKD’s RSI amounts to 29.00.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) declined sharply, trimming gains after the initiation of dosing in a Phase 1 multiple dose clinical trial of APD811. The company has a market value of $2.07 billion.

It employs 266 people, over the last 12 months has generated revenue of $29.70 million and has a net income of -$97.92 million. The firm’s operating margin is -207.78 percent and net profit margin -320.17 percent. The latest closing price of its shares moved up 10.95% from the 50-day moving average.

Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) faced a steep fall after pricing public offering of 17.5M shares. For this company, a return on equity of -52.72 percent was realized due to the financial situation. Last twelve months earnings per share reached a value of -$0.29. The stock closed at $2.26, down -0.24 points or -9.60% from previous close and at a distance of -9.62% from 20-day simple moving average.

Peregrine Pharmaceuticals (NASDAQ PHM) slipped yesterday, slicing gains on Wednesday after it provided a company update on financing activities, its contract manufacturing business and upcoming potential clinical milestones. In the last trading session, the stock’s price moved -33.97% below its 200 day moving average, changing hands as low as $0.74 per share.

The stock is currently trading -67.33% down its SMA 50. The worst hit in its 52 week range is $0.39 per share, with $5.50 being the 52 week best price, which compares with a latest closing price of $0.775. The Beta of this stock is 0.67.